Asia Pacific Biopharmaceuticals Market Forecast to 2028 -Regional Analysis - by Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Re

Asia Pacific Biopharmaceuticals Market Forecast to 2028-Regional Analysis- by Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)

The Asia Pacific biopharmaceuticals market was valued at US$ 39.96 billion in 2022 and is expected to reach US$ 94.13 billion by 2028. It is estimated to register a CAGR of 15.3% from 2022 to 2028.

Accelerated Clinical Trials to Offer Lucrative Opportunities for Asia Pacific Biopharmaceutical Market

Accelerated progress of clinical trials will ultimately result in the development and commercialization of new drugs targeting rare as well as commonly inherited diseases. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive, acute leukemia that has been historically difficult to diagnose. In December 2018, Tagraxofusp became the first therapy approved for treating BPDCN, which then became the standard care method. During clinical trials, more than 90% of patients who never received any treatment responded to therapy. Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that weakens muscles, impacts physical function, and causes irreversible brain and spinal cord damage. To date, only 2 products are approved for slowing the functional decline associated with ALS. The accelerated clinical trials for developing new products targeting ALS are in progress. For example, antisense oligonucleotides (ASOs) have been showing promising results in clinical trials involving patients suffering from ALS. Further, different gene therapy approaches, targeting multiple mutations in patients for both sporadic ALS and familial ALS, are in clinical trials. Thus, clinical trials of an extensive pipeline of biopharmaceuticals are expected to offer lucrative growth opportunities to the Asia Pacific biopharmaceuticals market in the coming years.

Asia Pacific Biopharmaceutical Market Overview

The Asia Pacific biopharmaceuticals market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China held the largest share of the market in 2021, and India is expected to exhibit a significant growth in the market. This is due to China's biopharmaceutical industry undergoing a tremendous shift evolving from a generics-focused to a thriving innovation hub. According to the Information Technology & Innovation Foundation (ITIF) report, China has made considerable progress in matching the US in innovation. A decade ago, China was 80% behind the US; however, today, it is just 50% owing to dramatic progress in innovation, technology influx, and favorable state-directed industrial and trade policies.

Asia Pacific Biopharmaceutical Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Biopharmaceutical Market Segmentation

The Asia Pacific biopharmaceutical market is segmented into product type, application, and country.

Based on product type, the Asia Pacific biopharmaceutical market is segmented into monoclonal antibodies, recombinant vaccines, conventional vaccines, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, recombinant enzymes, cell & gene therapies, cytokines/interferon/interleukins, and others. In 2022, the monoclonal antibodies segment held the largest share of the Asia Pacific biopharmaceutical market.

The recombinant vaccines segment is further segmented into cancer vaccine, malaria vaccine, ebola vaccine, hepatitis-B vaccine, tetanus vaccine, diphtheria vaccine, cholera vaccine, and others. The conventional vaccines segment is subsegmented into polio vaccine, pox vaccine, and others. The recombinant growth factors segment is further segmented into erythropoietin and granulocyte colony stimulating factor. The purified proteins segment is further divided into leukemia inhibitory factor (LIF), P53 protein, P38 protein, and others. The recombinant proteins segment is further segmented into serum albumin, amyloid protein, defensin, and transferrin. The recombinant hormones segment is further segmented into recombinant human growth hormones, recombinant insulin, and other recombinant hormones. The recombinant enzymes segment is further categorized into enterokinase, cyclase, caspase, and cathepsin. The cell & gene therapies segment is further divided into allogenic products, autologous products, and acellular products.

Based on application, the Asia Pacific biopharmaceutical market is segmented into oncology, inflammatory & infectious disease, autoimmune disorders, metabolic disorders, hormonal disorders & growth failure, cardiovascular diseases, neurological diseases, and others. In 2022, the oncology segment held the largest share of the Asia Pacific biopharmaceutical market.

Based on country, the Asia Pacific biopharmaceutical market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. In 2022, China held the largest share of the Asia Pacific biopharmaceutical market.

AbbVie Inc, AGC Biologics AS, Amgen Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, Eli Lilly and Co, Johnson & Johnson, Lonza Group AG, Thermo Fisher Scientific Inc, and WuXi Biologics Inc are among the leading companies operating in the Asia Pacific biopharmaceutical market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific biopharmaceutical market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific biopharmaceutical market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the biopharmaceutical market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution